• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Global Ovarian Cancer Market 2014-2018 - Product Image

Global Ovarian Cancer Market 2014-2018

  • ID: 2880838
  • June 2014
  • Region: Global
  • 45 pages
  • TechNavio


  • Aetera Zenteris Inc.
  • Aprea AB
  • Boehringer Ingelheim GmbH
  • F. Hoffman-La Roche Ltd
  • GlaxoSmithKline plc
  • Nektar Therapeutics
  • MORE

About Ovarian Cancer and its therapy

Ovarian cancer is a condition where a malignancy forms in the ovarian tissue and is caused by uncontrollable cell growth. It is one of the major gynaecological cancers worldwide and a leading cause of death. Ovarian cancer is difficult to diagnose in the initial stages because the symptoms are similar to that of gastric disorders like bloating, abdominal discomfort, difficulty in eating in the early stage and nausea, vomiting, constipation and diarrhoea in the later stages. It is often diagnosed in advanced stages when the metastasis has set in because the diagnostic techniques are not well-developed. Ovarian cancer can be treated by using chemotherapy, targeted therapy, and surgery. Although the market has a limited number of drugs for the treatment of ovarian cancer currently, a strong product pipeline is in development for the forecast period.

The analysts forecast the Global Ovarian Cancer market will grow at a CAGR of 13.85 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Ovarian Cancer market for the period 2013–2018. To calculate READ MORE >


  • Aetera Zenteris Inc.
  • Aprea AB
  • Boehringer Ingelheim GmbH
  • F. Hoffman-La Roche Ltd
  • GlaxoSmithKline plc
  • Nektar Therapeutics
  • MORE

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Rate of Incidence and Prevalence
08. Market Segmentation by Type of Therapy
08.1.1 Chemotherapy
08.1.2 Targeted Therapy
09. Pipeline Portfolio
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Ovarian Cancer Market 2013-2018 (US$ billion)
Exhibit 3: Global Ovarian Cancer Market 2013-2018 by Type of Therapy
Exhibit 4: Snapshot of Ovarian Cancer Pipeline 2013
Exhibit 5: Global Ovarian Cancer Market by Geographical Segmentation 2013


  • Aetera Zenteris Inc.
  • Aprea AB
  • Boehringer Ingelheim GmbH
  • F. Hoffman-La Roche Ltd
  • GlaxoSmithKline plc
  • Nektar Therapeutics
  • MORE

Commenting on the report, an analyst from the team said: “There is increased funding in the US for R&D activities for ovarian cancer. Organizations such as the OCRF and the OCNA are the oldest that fund research into ovarian cancer in the US. The National Institutes of Health and the National Cancer Institute are known to invest at least US$100 million per annum into research on ovarian cancer. Thus the increase in funding for ovarian cancer research is a major trend that will add to the growth of the market.”

According to the report, one of the major drivers is a promising drug pipeline. The promising pipeline within the forecast period is expected to display superior safety efficacy results. There are many drugs in the pipeline from companies such as Merck Co. Inc., MEI Pharma Inc., Bionumerik Pharmaceuticals Inc., Amgen Inc., Oasmia Pharmaceutical AB, and Synta Pharmaceuticals Corp. The introduction of new drugs will drive market growth.
Further, the report states that lack of accurate diagnosis for ovarian cancer is one of the major challenges. The delay in diagnosis of ovarian cancer leads to a delay in treatment, which is a major drawback to the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

- Bristol Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline plc
- Janssen Pharmaceuticals Inc.
- F. Hoffman-La Roche Ltd
- Aprea AB
- Aetera Zenteris Inc.
- Amgen Inc.
- Astra Zeneca plc
- Bionumerik Pharmaceuticals Inc.
- Boehringer Ingelheim GmbH
- Genentech Inc.
- MEI Pharmaceuticals Inc.
- Nektar Therapeutics
- NeoPharm Inc.
- Novogen Inc.
- Oasmia Pharmaceuticals AB
- Synta Pharmaceuticals Corp.

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos